HR positive

Given the tumour's low-grade, hormone-receptor-positive biology and microscopic radial margin involvement, adjuvant endocrine therapy with letrozole (2.5 mg daily) was initiated...Accurate diagnosis and optimal management depend on comprehensive histology and immunohistochemistry, supported by fusion-gene testing, to guide individualised surgical and adjuvant management. Given the tumour's potential for very late relapse, prolonged surveillance is warranted despite the favourable short-term outcome.

Future progress will depend on biomarker-driven patient selection and prospective validation. Redefining success in HER2+ MBC to include not only survival but also quality of life and sustainability represents an important step toward patient-centered cancer care.

Living in lower-income and lower-education areas and use of public or lack of insurance were associated with heterogeneous delays across subtypes and treatment modalities. This cross-sectional study of patients with dnMBC found racial and ethnic disparities in disease presentation and inequities in timely treatment for dnMBC across subtypes, emphasizing the need for tailored interventions to improve care delivery and outcomes.

The prognostic impact of serum inflammatory markers in hormone receptor-positive metastatic breast cancer is heterogeneous. Although no statistical significance was observed in our cohort, high LMR levels may provide predictive and prognostic value in treatment selection.

Our results highlight CDKN1B as a prognostic biomarker to guide CDK4/6-targeted therapy and a predictor of endocrine resistance in HR + /HER2- breast cancer.

Several of these candidates have entered early-phase clinical evaluation, marking a new era in CDK-targeted therapy. This review synthesizes recent preclinical and clinical advances, defines key challenges in optimizing efficacy and safety, and outlines future directions for integrating CDK-directed strategies within precision oncology frameworks.

P=N/A, N=30, Recruiting, Huizhou Central People's Hospital; Huizhou Central People's Hospital

P4, N=67, Recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | N=35 --> 67

P=N/A, N=1235, Not yet recruiting, Chirec

Patients with HR+/HER2- ABC receiving palbociclib with higher comorbidity burden, especially blood and lymphatic system disorders, had poorer clinical outcomes. GHS/QoL was preserved regardless of comorbidity burden.

Capecitabine and paclitaxel demonstrated comparable efficacy after CDK4/6i progression, with no significant differences in PFS or OS. Given their distinct toxicity profiles, treatment selection should be individualized according to patient characteristics and tolerability.

P3, N=315, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2027 --> Sep 2028